Testing effectiveness (Phase 2)Study completedNCT03684811
What this trial is testing
FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Who this might be right for
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)Cohort 3a and 3b: Chondrosarcoma+2 more
Forma Therapeutics, Inc. 93